Prostate cancer, also known as carcinoma of the prostate, is the development of cancer in the prostate, a gland in the male reproductive system. Immunotherapy is a kind of new therapy method which help human resist tumor by using the immune system, decreasing the side-effect of traditional therapy. However, why the effective of anti-androgenic therapy combined with immunotherapy cannot achieve the expectation.
Cooperating with Prof. Yangxin Fu, University of Texas Southwestern Medical Center and Dr. Xuanming Yang, Shanghai Jiaotong University, Doctoral Student in School of Bioscience and Bioengineering, South China University, Pu Yang, published a paper in Science Series Journal-Science Translational Medicine as the first author. In this paper, they did the experiment using mice with prostate cancer and health immune system, and found that when nonsteroidal antiandrogen antagonist drugs applied with immunotherapy, the effective is not as well as immunotherapy itself.
The research detailed found that the mechanism of nonsteroidal antiandrogen antagonist drugs immune response inhibition effect is that it can retain the activation of T cells as a kind of immune cell receptor, which furtherly inhibit the tumor immunoreaction. When patients cannot produce proper immune response, tumor treatment will be more prone to be resisted and tumor will be easier to relapse.
Pu Yang’s research illustrate that anticancer drugs always found targeting tumor cells and accomplished by high throughput screening. Researchers rarely think about the effects to immune system, while this field cannot be ignored in tumor therapy.